益气养阴方联合化疗治疗晚期胃癌疗效观察及对免疫功能的影响  

Clinical Observation of Yiqi Yangyin Prescription Combined with Chemotherapy for Advanced Gastric Cancer and Its Effect on Immune Function

作　　者：王俊涛[1] 尹怡[1] 李晓婷[1] 王祥麒[1] WANG Juntao;YIN Yi;LI Xiaoting;WANG Xiangqi

机构地区：[1]河南中医药大学第三附属医院,河南郑州450000

出　　处：《新中医》2018年第11期171-173,共3页New Chinese Medicine

摘　　要：目的:观察自拟益气养阴方联合XELOX方案化疗对晚期胃癌的临床疗效及免疫功能的影响。方法:将95例晚期胃癌患者随机分为2组,对照组46例采用XELOX方案单纯化疗,观察组49例在对照组治疗的基础上加益气养阴方进行治疗;2组均以28天为1周期,共治疗2个周期。观察比较2组近期临床疗效、患者Karnofsky功能状态(KPS)评分、生命质量调查量表(QLQ-C30)评分、免疫功能变化及不良反应情况。结果:近期疗效总有效率观察组为78.26%,对照组为69.39%,2组比较,差异无统计学意义(P> 0.05)。治疗后2组患者KPS、QLQ-C30评分均较治疗前升高(P <0.05),且观察组上述评分升高较对照组更显著(P <0.05)。治疗后,观察组总T细胞、Th细胞及Th/Ts比例较对照组高,2组比较,差异均有统计学意义(P <0.05);而2组患者Ts细胞比较,差异无统计学意义(P> 0.05)。消化道不良反应发生率观察组为36.96%,对照组为59.18%,2组比较,差异有统计学意义(P <0.05);而2组患者白细胞降低率、血小板减少率、肝功异常率及肾功损害率比较,差异均无统计学意义(P> 0.05)。结论:益气养阴方联合XELOX方案化疗可提高晚期胃癌患者生活质量及免疫功能,减少化疗后消化道不良反应。Objective- To observe the clinical effect of Yiqi Yangyin prescription combined with XELOX method of chemotherapy for advanced gastric cancer and the effect on immune function. Methods： Divided 96 cases of patients with advanced gastric cancer into two groups randomly. The 46 cases in control group were given simple XELOX method of chemotherapy, while the 49 cases in observation group were additionally given the Yiqi Yangyin prescription. The treatment for the two groups lasted for 2 courses, 28 days as a course. Observed and compared the short-term clinical effect in the two groups, score of Karnofsky functional status （KPS）, score of quality investigation of quality of life （QLQ-c30）, changes of immune function and adverse reactions. Results： The short-term total effective rate was 78.26% in the observation group and 69.39% in the control group, there was no significant difference betng tounct in the companson of the two groups （P〉0.05）. After treatment, the KPS and QLQ-C30 scores in the two groups were increased when compared with those before treatment （P 〈 0.05）, and the increase of the scores mentioned above in the observation group was more significant than that in the control group （P 〈 0.05）. After treatment, the total Tcells, Th cells and proportion of Th/Ts in the observation group was higher than that in the control group, compared the two groups, difference being significant （P 〈 0.05）. There was no significant difference being found in the comparison of Ts cells in the two groups （P 〉 0.05）. The incidence of gastrointestinal adverse reactions was 36.96% in the observation group and 69.18% in the control group, compared the two groups, difference being significant （P 〈 0.06）. There was no significant difference being found in the comparisons of reduction rates of leukopenia and platelet, the Liver dysfunction rate and renal function damage （P 〉 0.05）. Conclusion： Yiqi Yangyin prescription combined with XELOX method of chemotherapy can improve th

关 键 词：胃癌 XELOX方案 益气养阴方 KPS评分 QLQ-C30评分 免疫功能 

分 类 号：R735.2[医药卫生—肿瘤]